Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX / TSX: EPRX) has released updated 52-week and 36-week clinical data from the highest-dose cohorts of its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The release states that 64% of patients across cohorts 5–9 — nine of 14 — remained in clinical remission at 52 weeks following a single administration of EP-104GI. The data also showed a continued favourable safety profile, with no treatment-related serious adverse events reported to date, which investors may view as meaningful progress for the programme.

Key Points

  • Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX / TSX: EPRX) is a Vancouver-based clinical-stage biotechnology company
  • 52-week data from Cohort 9 (highest dose) showed 66% of patients maintaining clinical remission; overall 64% across cohorts 5–9 remained in remission at 52 weeks
  • No treatment-related serious adverse events, no oropharyngeal candidiasis, and no glucose derangement were observed across all ten cohorts to date
  • Investors may watch for Phase 2b interim data expected in December 2026 and additional Phase 1b/2a disclosures in the coming months

EP-104GI Symptom Remission Rates Across RESOLVE Cohorts 5–9

The RESOLVE trial measures symptom response using the Straumann Dysphagia Index (SDI), where a reduction of at least three points from baseline defines clinical remission. The announcement reports that in Cohort 9 (20 x 8 mg dose, n=3), the mean SDI reduction was 3.0 at both 36 and 52 weeks. Across the broader cohorts 5–9, clinical remission rates were 53% at 12 weeks, 78% at 24 weeks, 61% at 36 weeks, and 64% at 52 weeks. The disclosure notes that 66% of Cohort 9 patients — two of three — maintained clinical remission at the 52-week mark.

Histologic Tissue Outcomes in Cohort 8b at 36 Weeks

Tissue health was assessed using the Eosinophilic Esophagitis Histology Scoring System (EoEHSS), which evaluates both the grade and stage of inflammatory and fibrotic disease features. New data reported for Cohort 8b (20 x 6 mg dose, n=4) showed mean EoEHSS stage and grade reductions of -0.26 and -0.27, respectively, at 36 weeks. The release states these findings are consistent with histologic responses observed across all cohorts analysed to date, suggesting that the improved injection technique used to distinguish Cohort 8b from Cohort 8 may be contributing to sustained tissue-level improvements.

Safety Profile of EP-104GI Powered by Diffusphere™ Technology

Eupraxia's EP-104GI is formulated using the company's proprietary Diffusphere™ controlled drug-delivery platform. The announcement reports that across all ten cohorts evaluated so far, no treatment-emergent or procedure-related serious adverse events have been observed. No cases of oropharyngeal candidiasis — a commonly reported side effect of swallowed steroids — adrenal insufficiency, or glucose derangement were detected. The company states EP-104GI has been generally well tolerated at all dose levels, including the highest dose of 8 mg per site across 20 injection sites used in Cohort 9.

Phase 2b Randomised Trial Actively Recruiting

The Phase 2b portion of the RESOLVE trial — a randomised, placebo-controlled study — is currently recruiting participants across two dose arms: 120 mg (20 x 6 mg) and 160 mg (20 x 8 mg). The company announced interim data from this phase are expected in December 2026. The Phase 1b/2a portion remains ongoing, and the company has indicated additional data from that open-label segment will be disclosed in the coming months. The immediate share price impact was not clear from available public information.